Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye

PURPOSE: To assess adherence, non-persistence, discontinuation, and switching of topical cyclosporine ophthalmic emulsion 0.05% (CYC) and lifitegrast ophthalmic solution 5% (LIF) use in the real world among patients with dry eye disease (DED). DESIGN: Retrospective insurance claims study. METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: White, Darrell E, Zhao, Yang, Ogundele, Abayomi, Fulcher, Nicole, Acs, Annabel, Moore-Schiltz, Laura, Karpecki, Paul M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878923/
https://www.ncbi.nlm.nih.gov/pubmed/31819353
http://dx.doi.org/10.2147/OPTH.S226168
_version_ 1783473534323916800
author White, Darrell E
Zhao, Yang
Ogundele, Abayomi
Fulcher, Nicole
Acs, Annabel
Moore-Schiltz, Laura
Karpecki, Paul M
author_facet White, Darrell E
Zhao, Yang
Ogundele, Abayomi
Fulcher, Nicole
Acs, Annabel
Moore-Schiltz, Laura
Karpecki, Paul M
author_sort White, Darrell E
collection PubMed
description PURPOSE: To assess adherence, non-persistence, discontinuation, and switching of topical cyclosporine ophthalmic emulsion 0.05% (CYC) and lifitegrast ophthalmic solution 5% (LIF) use in the real world among patients with dry eye disease (DED). DESIGN: Retrospective insurance claims study. METHODS: Adult patients with DED and ≥1 prescription claim for CYC or LIF (first claim = index date) in the IBM(®) MarketScan(®) databases from July 2016 to February 2018 were identified. Eligible patients had continuous medical and pharmacy benefits in the 12 months pre- and post-index periods, and no prior use of the index medication. The proportion of days covered (PDC), adherence, non-persistence, discontinuation, and switching were examined over the 12-month post-index period. RESULTS: This study included 6537 CYC and 3235 LIF patients. The adherence rate was 5.9% for CYC and 9.7% for LIF; the median PDC was 0.3 for both cohorts. Overall, 70.8% of CYC and 64.4% of LIF patients discontinued treatment with median days to discontinuation of 89 and 29, respectively. Non-persistence was 7.1% for CYC and 6.8% for LIF (median days to discontinuation: 89 and 105). In addition, 5.0% switched from CYC to LIF, and 9.6% switched from LIF to CYC over the post-index period. CONCLUSION: Over 60% of DED patients discontinued treatment within 12 months of initiation; the median time to discontinuation was 3 months for CYC and 1 month for LIF. Although this analysis did not capture the reasons why patients discontinued treatment, the results demonstrate there likely exists a significant unmet need amongst DED patients.
format Online
Article
Text
id pubmed-6878923
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-68789232019-12-09 Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye White, Darrell E Zhao, Yang Ogundele, Abayomi Fulcher, Nicole Acs, Annabel Moore-Schiltz, Laura Karpecki, Paul M Clin Ophthalmol Original Research PURPOSE: To assess adherence, non-persistence, discontinuation, and switching of topical cyclosporine ophthalmic emulsion 0.05% (CYC) and lifitegrast ophthalmic solution 5% (LIF) use in the real world among patients with dry eye disease (DED). DESIGN: Retrospective insurance claims study. METHODS: Adult patients with DED and ≥1 prescription claim for CYC or LIF (first claim = index date) in the IBM(®) MarketScan(®) databases from July 2016 to February 2018 were identified. Eligible patients had continuous medical and pharmacy benefits in the 12 months pre- and post-index periods, and no prior use of the index medication. The proportion of days covered (PDC), adherence, non-persistence, discontinuation, and switching were examined over the 12-month post-index period. RESULTS: This study included 6537 CYC and 3235 LIF patients. The adherence rate was 5.9% for CYC and 9.7% for LIF; the median PDC was 0.3 for both cohorts. Overall, 70.8% of CYC and 64.4% of LIF patients discontinued treatment with median days to discontinuation of 89 and 29, respectively. Non-persistence was 7.1% for CYC and 6.8% for LIF (median days to discontinuation: 89 and 105). In addition, 5.0% switched from CYC to LIF, and 9.6% switched from LIF to CYC over the post-index period. CONCLUSION: Over 60% of DED patients discontinued treatment within 12 months of initiation; the median time to discontinuation was 3 months for CYC and 1 month for LIF. Although this analysis did not capture the reasons why patients discontinued treatment, the results demonstrate there likely exists a significant unmet need amongst DED patients. Dove 2019-11-22 /pmc/articles/PMC6878923/ /pubmed/31819353 http://dx.doi.org/10.2147/OPTH.S226168 Text en © 2019 White et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
White, Darrell E
Zhao, Yang
Ogundele, Abayomi
Fulcher, Nicole
Acs, Annabel
Moore-Schiltz, Laura
Karpecki, Paul M
Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
title Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
title_full Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
title_fullStr Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
title_full_unstemmed Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
title_short Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
title_sort real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878923/
https://www.ncbi.nlm.nih.gov/pubmed/31819353
http://dx.doi.org/10.2147/OPTH.S226168
work_keys_str_mv AT whitedarrelle realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye
AT zhaoyang realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye
AT ogundeleabayomi realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye
AT fulchernicole realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye
AT acsannabel realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye
AT mooreschiltzlaura realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye
AT karpeckipaulm realworldtreatmentpatternsofcyclosporineophthalmicemulsionandlifitegrastophthalmicsolutionamongpatientswithdryeye